Stay updated with breaking news from Simon Cork. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drugs like Ozempic, which have become increasingly popular for losing weight, heighten the risk of certain severe gastrointestinal problems including stomach paralysis, according to a large study published Thursday.The GLP-1 agonists were associated with an almost four times increased risk of stomach paralysis, a nine times higher risk of pancreatitis and four times greater risk of bowel obstruction.
A new study suggests people taking popular injected medications for weight loss, including Wegovy, Ozempic, Saxenda and Victoza, may be at higher risk for serious digestive problems such as stomach
Compared with naltrexone/bupropion for weight loss, semaglutide and liraglutide were associated with a higher risk for three adverse gastrointestinal outcomes.
GLP-1 agonists have soared in popularity in recent years as a means to lose weight
Danish pharma group Novo Nordisk's obesity drug Wegovy cuts the risk of heart attacks and strokes by a fifth, the company said in an announcement Tuesday that sent its shares soaring to a record high.